Has James Ferrara received payments from drug or device companies?

Yes. Drug and device makers reported $117,706 in general payments to James Ferrara across 88 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Ferrara did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Ferrara come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Ferrara

Pediatric Hematology-Oncology · New York, NYNPI 1013927649

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $100,764 of the $117,706 with a category attached, or 85.6%. 15 manufacturers reported payments, led by AstraZeneca at 43.3% of the total. Reporting peaked in 2019 at $49,035 and has fallen 68.0% since, to $15,687 in 2025. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$117,706in general payments, 2019–2025

Across 88 payments — averaging $1337.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$51K
Mallinckrodt Enterprises LLC$21K
Incyte Corporation$16K
Sanofi$9K
Modernatx, Inc.$6K
Kamada Ltd.$5K
plus $10K from 9 others

$334,240in research payments, 2019–2025

Across 8 payments — averaging $41,780 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$327K
AstraZeneca$7K

What the payments were for

Consulting fees$100,76486%
Speaking & faculty fees$10,2999%
Travel & lodging$3,4133%
Food & beverage$3,2303%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	21	$51,013
Mallinckrodt Enterprises LLC	8	$20,663
Incyte Corporation	26	$15,872
Sanofi	2	$9,346
Modernatx, Inc.	2	$6,000
Kamada Ltd.	1	$4,625
Omeros Corporation	2	$4,500
National Marrow Donor Program	5	$1,603
CSL Behring	2	$1,200
Sanofi-aventis U.S. LLC	4	$1,132
Takeda Pharmaceuticals U.S.A., Inc.	7	$613
Aimmune Therapeutics, Inc.	1	$544
Genentech, Inc.	3	$264
Genentech USA, Inc.	2	$261
GE HealthCare	2	$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ULTOMIRIS$51,013
THYMOGLOBULIN$10,393
narsoplimab$4,500
VOWST$544
ICLUSIG$225
JAKAFI$113
NINLARO$110

How this compares

$117,706 in reported general payments places this provider in the 95th percentile of 196 pediatric hematology-oncology providers in New York.

See all pediatric hematology-oncology providers in New York →

Other pediatric hematology-oncology in New York

Sujit ShethNew York$359K
Jaap Jan BoelensNew York$303K
James BusselNew York$204K
Saara KavianyNew York$144K
Gary BrittenhamNew York$137K
John LevineNew York$98K
Nai-Kong CheungNew York$86K
Andrew HarrisNew York$85K
Joseph OvedNew York$77K
Catherine McGuinnNew York$67K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →